Dr. Peter Bach Endorses Delinkage for Orphan Drugs

Posted on 15 November 201621 November 2016 by Zack Struver

At an October 21, 2016 Partnership for Quality Care drug pricing forum at the Kaiser Permanent Center for Total Health in Washington, D.C., Dr. Peter Bach, the Director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, endorsed the idea of delinkage in connection with his proposals on value-based pricing. In particular, Read more about Dr. Peter Bach Endorses Delinkage for Orphan Drugs[…]

UN High-Level Panel Endorses Delinkage of R&D Costs from Prices of Drugs and Vaccines

Posted on 14 September 201616 September 2016 by Zack Struver

The United Nations Secretary-General’s High-Level Panel on Access to Medicines today issued its final report. The main report was accompanied by eleven pages of additional commentary, including ares of dissent from six panel members, plus additional explanations of the process. The panel was asked to address the policy incoherence from granting monopolies for products on Read more about UN High-Level Panel Endorses Delinkage of R&D Costs from Prices of Drugs and Vaccines[…]

Delinkage

Fund Innovation Without High Drug Prices